NewEdge Wealth LLC Buys Shares of 3,394 Insulet Corporation $PODD

NewEdge Wealth LLC purchased a new position in Insulet Corporation (NASDAQ:PODD) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 3,394 shares of the medical instruments supplier’s stock, valued at approximately $517,000.

A number of other institutional investors have also recently bought and sold shares of the company. Glenmede Investment Management LP increased its position in Insulet by 1.6% during the third quarter. Glenmede Investment Management LP now owns 2,292 shares of the medical instruments supplier’s stock worth $708,000 after buying an additional 35 shares during the last quarter. Curi Capital LLC boosted its stake in shares of Insulet by 0.8% during the 2nd quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock worth $1,365,000 after acquiring an additional 36 shares in the last quarter. Great Lakes Advisors LLC boosted its stake in shares of Insulet by 1.5% during the 4th quarter. Great Lakes Advisors LLC now owns 2,784 shares of the medical instruments supplier’s stock worth $791,000 after acquiring an additional 40 shares in the last quarter. Camarda Financial Advisors LLC increased its holdings in shares of Insulet by 0.5% during the 2nd quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier’s stock valued at $2,304,000 after acquiring an additional 40 shares during the last quarter. Finally, Larson Financial Group LLC increased its holdings in shares of Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 47 shares during the last quarter.

Insulet Stock Performance

NASDAQ:PODD opened at $148.16 on Friday. Insulet Corporation has a 12-month low of $126.40 and a 12-month high of $354.88. The company has a quick ratio of 1.83, a current ratio of 2.48 and a debt-to-equity ratio of 0.65. The firm has a 50-day moving average price of $154.67 and a 200 day moving average price of $184.81. The firm has a market capitalization of $10.27 billion, a PE ratio of 27.69, a price-to-earnings-growth ratio of 1.17 and a beta of 1.10.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 EPS for the quarter, topping analysts’ consensus estimates of $1.47 by $0.19. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The company had revenue of $801.70 million for the quarter, compared to analyst estimates of $787.39 million. During the same quarter in the previous year, the firm earned $1.17 earnings per share. The business’s revenue was up 23.5% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.460- EPS. Research analysts anticipate that Insulet Corporation will post 6.51 earnings per share for the current fiscal year.

Key Stories Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Neutral Sentiment: Pomerantz said a class action has been filed in the U.S. District Court for the District of Massachusetts under docket 26-cv-13062. The proposed class generally covers investors who purchased Insulet securities between February 21, 2025, and May 26, 2026, and seeks damages under Sections 10(b) and 20(a) of the Securities Exchange Act. Pomerantz class action filing
• Neutral Sentiment: Several law firms—including DJS Law Group, Schall Brown & Schwartz, Robbins Geller, Faruqi & Faruqi, Rosen, Bronstein Gewirtz & Grossman, and Bernstein Liebhard—reminded shareholders of an August 31 deadline to seek appointment as lead plaintiff. These announcements are primarily investor solicitations rather than new operational developments. Robbins Geller investor deadline
• Negative Sentiment: The allegations center on purportedly false or misleading statements about Insulet’s manufacturing quality and product safety. One investor notice linked the claims to two Omnipod medical-device corrections and reported substantial share-price declines following corrective disclosures. If the case advances, Insulet could face litigation expenses, potential damages, reputational harm, and additional scrutiny of its products and disclosures. Insulet shareholder lawsuit allegations

Insider Buying and Selling at Insulet

In related news, Director Timothy C. Stonesifer bought 2,790 shares of Insulet stock in a transaction dated Wednesday, June 3rd. The shares were bought at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the transaction, the director owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Corporate insiders own 0.36% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on PODD shares. Benchmark reduced their target price on Insulet from $250.00 to $185.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Weiss Ratings downgraded Insulet from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, June 24th. Canaccord Genuity Group dropped their price target on shares of Insulet from $249.00 to $179.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. TD Cowen reduced their price objective on shares of Insulet from $294.00 to $144.00 and set a “hold” rating for the company in a research note on Thursday, August 6th. Finally, Evercore set a $180.00 price objective on shares of Insulet in a report on Monday, July 6th. Fourteen equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Insulet has an average rating of “Hold” and an average target price of $195.40.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.